Aktuellt
SENASTE
Curasight's report does not bring material news; the highlights of the report were announced earlier in the quarter. Pre-clincal results with uTREAT in brain cancer, positive phase II clinical trial outcomes with uTRACE in brain cancer and the partnership agreement with Curium. The full results from the phase II trial will be presented later in September this year. We maintain our rNPV-SOTP mid-point value of DKK 54 as we await the results.
LÄS MER
